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Therapy response monitoring of the early
effects of a new BRAF inhibitor on melanoma
xenograft in mice: evaluation of 18F-FDG-PET
and 18F-FLT-PET
Edwin J. W. Gevena, Stefan Eversb, Tapan K. Nayakc, Mats Bergströmc,
Fei Sud, Danny Gerritsa, Gerben M. Franssena and Otto C. Boermana*
Inhibition of the V600E mutated BRAF kinase gene (BRAFV600E) is an important and effective approach to treating
melanomas. A new speciﬁc small molecule inhibitor of BRAFV600E, PLX3603, showed potent melanoma growth-
inhibiting characteristics in preclinical studies and is currently under clinical investigation. In this study we investi-
gated the feasibility of 18F-FDG and 18F-FLT-PET to monitor the early effects of the BRAFV600E inhibitor in mice with
melanoma xenografts. SCID/beige mice with subcutaneous (s.c.) A375 melanoma xenografts, expressing BRAFV600E,
received the BRAFV600E inhibitor twice daily orally (0, 25, 50 and 75mg/kg). At 1, 3 and 7days after start of therapy,
the uptake of 18F-FDG and 18F-FLT in the tumor and normal tissues was determined in ex vivo tissue samples. Serial
18F-FDG and 18F-FLT-PET scans were acquired of animals at 1 day before and 1, 3 and 7days after start of treatment
with 75mg/kg BRAFV600E inhibitor. A dose-dependent decrease in 18F-FDG uptake in the A375 tumors was observed
by ex vivo biodistribution analysis. Administration of 75mg/kg BRAF inhibitor for 1, 3 and 7days resulted in a sig-
niﬁcantly decreased 18F-FDG uptake in A375 tumors (41, 35 and 51%, respectively). 18F-FLT uptake in the A375 tu-
mors was low at baseline and no signiﬁcant changes in 18F-FLT uptake were observed at any of the doses
administered. These effects were corroborated by serial in vivo 18F-FDG and 18F-FLT-PET imaging. These data dem-
onstrate that 18F-FDG-PET can be used as an imaging biomarker to noninvasively evaluate the early effects of
PLX3603. Copyright © 2014 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Metastatic melanoma is an aggressive disease and patients have
a poor prognosis. The median survival time for patients with me-
tastasized melanoma is a mere 8–9 months and 3-year survival is
<15% (1). Only a few effective therapies for metastatic mela-
noma are available, such as chemotherapy with decarbazine
and immunotherapy with interferon-α and interleukin-2, al-
though their advantages in terms of survival and response rate
are moderate.
In the search for new therapy targets, a genomic screen for
mutations in signaling molecules in melanoma revealed numer-
ous mutations, particularly in members of the mitogen-activated
protein kinase (MAPK) pathway (2). Mutations in the NRAS gene
have been observed in ~20% of all melanomas, whereas muta-
tions in the BRAF gene have been observed in ~50% of all mel-
anomas. These mutations lead to constitutive kinase activation,
independent of upstream signaling. This continuous activation
of the NRAS/BRAF/MAPK/ERK signal transduction pathway stim-
ulates melanocyte proliferation and is therefore a key driving
force for the development of melanoma. Nearly 90% of all of
the mutations observed in the BRAF gene are a single-point mu-
tation, which results in a valine-to-glutamic acid substitution at
residue 600 (BRAFV600E). Owing to its high prevalence, the selec-
tive inhibition of the oncogenic BRAFV600E is a prime therapeutic
approach for treatment of metastatic melanoma (3).
Vemurafenib (PLX4032) is the ﬁrst selective small molecule in-
hibitor of BRAFV600E that has been approved for clinical use to treat
patients with BRAFV600E-positive metastatic melanoma. In clinical
trials, treatment with vemurafenib resulted in a response rate of
53–81%, a median overall survival (OS) of 13.2–15.9months, a
median progression-free survival (PFS) of 6.9months and a 63%
decrease in risk of death compared with treatment with
decarbazine (median OS of 9.6months and a median PFS of
1.6months) (4–7). Dabrafenib, another speciﬁc BRAFV600E inhibitor,
showed similar clinical response rates (50%) and median PFS
(5.1months) to vemurafenib (8). Although not life-threatening,
* Correspondence to: O. C. Boerman, Department of Radiology and Nuclear
Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
E-mail: otto.boerman@radboudumc.nl
a E. J. W. Geven, D. Gerrits, G. M. Franssen, O. C. Boerman
Department of Radiology and Nuclear Medicine, Radboud University Medical
Center, Nijmegen, The Netherlands
b S. Evers
Roche Glycart AG, Schlieren, Switzerland
c T. K. Nayak, M. Bergström
F. Hoffmann-La Roche AG, pRED, Basel, Switzerland
d F. Su
F. Hoffmann-La Roche Ltd, Nutley, USA
Full Paper
Received: 6 February 2014, Revised: 24 June 2014, Accepted: 31 July 2014, Published online in Wiley Online Library: 9 September 2014
(wileyonlinelibrary.com) DOI: 10.1002/cmmi.1619
Contrast Media Mol. Imaging 2015, 10 203–210 Copyright © 2014 John Wiley & Sons, Ltd.
203
treatment with vemurafenib and dabrafenib may result in serious
adverse events, including the increased incidence of cutaneous
squamous cell carcinoma (cuSCC, in approximately 20% of the
patients) and keratoacanthoma and the possible subsequent
development of additional malignant lesions (9).
Recently, a new inhibitor of BRAFV600E (PLX3603) was devel-
oped, which in pre-clinical studies showed promising melanoma
growth-inhibiting characteristics. PLX3603 inhibited cell prolifer-
ation and MAPK signaling in several BRAFV600E-expressing cancer
cell lines more potently than vemurafenib and in mice with mel-
anoma xenografts it showed increased anti-tumor activity in vivo
compared with vemurafenib (10). More importantly, PLX3603
had no effect on the tumor growth of A431 SCC xenografts,
whereas vemurafenib treatment stimulated its growth (10). A
phase I clinical dose escalation study showed an improved safety
proﬁle for PLX3603 (11). No dose-limiting toxicities were ob-
served, adverse events were mild to moderate and only 7% of
the patients developed cuSCC (11). Efﬁcacy of PLX3603 treat-
ment was encouraging: 18 out of 44 patients showed stable dis-
ease, while 14 patients showed a partial response (11).
Continued activation of the MAPK-pathway, owing to mutated
BRAF, has been directly linked to activation of glucose metabo-
lism and proliferation. For instance, ERK stimulates glucose me-
tabolism via the LKB1-AMP pathway and the expression of the
glucose transporter, GLUT1 (12–14). Mutant BRAF positive cell
lines show a decreased expression of cyclin D1 and a complete
and rapid inhibition of the G1–S transition (15). These ﬁndings
suggest that the early effects of BRAFV600E inhibition can be
monitored by 2-deoxy-2-[18F]ﬂuoro-D-glucose (18F-FDG) or 3′-
deoxy-3′-[18F]ﬂuoro-L-thymidine-positron emission tomography
(18F-FLT-PET). In this study we investigate the feasibility of
18F-FDG and 18F-FLT-PET to monitor the effects of PLX3603 on
BRAFV600E-mutated melanoma in mice with s.c. tumors.
2. MATERIALS AND METHODS
2.1. BRAFV600E Inhibitor
PLX3603 (RO5212054, RG7256) is a novel, orally available,
small-molecule inhibitor of BRAFV600E and was synthesized at
Hoffmann–La Roche Inc. (Nutley, NJ, USA) (10). PLX3603 was
resuspended in 1% hydroxypropylcellulose, pH 4 (Klucel-LF,
Hercules Incorporated, Wilmington, DE, USA) and orally adminis-
tered within 30min after constitution of the suspension.
2.2. Cell Culture
The V600E mutant BRAF-expressing human melanoma cell line
A375 (CRL-1619, American Type Culture Collection, Manassas,
VA, USA) was cultured in Dulbecco’s modiﬁed Eagle medium,
high glucose (Gibco, Carlsbad, CA, USA) supplemented with fetal
calf serum (10%). Cells were incubated at 37 °C in 5% CO2 and
95% relative humidity.
2.3. Animals
All animal experiments described in this study were approved by
the institutional review board and conducted according to their
guidelines. Female SCID/beige mice were obtained from Taconic
Farms (Germantown, NY, USA) and weighed 20–25 g (6–8 weeks
old) upon arrival. Mice were allowed to acclimatize for 1week to
the new housing conditions. Mice were housed with ﬁve animals
per individual ventilated cage under standard housing
conditions (temperature 20–24 °C, 12 h light–dark cycle and ad
libitum access to animal chow and water).
2.4. 18F-FDG and 18F-FLT Biodistribution Analysis
Animals were s.c. injected with 10 × 106 A375 cells in the right
ﬂank. After 1week tumor xenografts were palpable. Tumor size
was measured twice weekly by digital calipers and calculated
as 4/3 · π · (length/2) · (width/2) · (height/2). Fourteen days after
cell inoculation tumor size reached an approximate volume of
30mm3 and PLX3603 treatment was started. Tumor size was
measured at 1, 3 and 7 days after the start of PLX3603 adminis-
tration. PLX3603 was administered orally twice daily at a 12 h in-
terval at doses of 25, 50 and 75mg/kg. The control group
received vehicle only (1% hydroxypropylcellulose, pH 4; n=5).
At 1, 3 and 7 days after the start of PLX3603 treatment (a total
of 3, 7 and 15 PLX3603 administrations, respectively), and 4 h af-
ter the last PLX3603 administration, the animals received 10MBq
18F-FDG or 18F-FLT intravenously (i.v.) via the tail vein. 18F-FDG
and 18F-FLT was obtained from BV Cyclotron VU (Amsterdam,
The Netherlands). Mice that received 18F-FDG were anesthetized
with 2% isoﬂurane–O2 and kept at 37 °C immediately after
18F-FDG injection. One hour after the 18F-FDG and 18F-FLT injec-
tion, the mice were euthanized by CO2/O2 asphyxiation, followed
by cardiac puncture to obtain blood. The A375 melanoma tumor
and other tissues of interest were dissected, weighed and counted
in a γ-counter (1480 Wizzard, Wallac, Waltham, MA, USA) with stan-
dards prepared from the injected solution. The percentage of
injected dose per gram tissue (%ID/g) was calculated.
2.5. 18F-FDG- and 18F-FLT-PET/CT
Two groups of mice with s.c. A375 tumors were treated with
PLX3603 at 75mg/kg as described above and PET/CT images
were acquired at various time points; 1 day prior to the start of
PLX3603 administration, 18F-FDG (n= 3) and 18F-FLT-PET/CT
(n= 3) scans were made. The 18F-FDG and 18F-FLT-PET/CT scans
was repeated in the same animals at 1, 3 and 7 days after the
start of PLX3603 administration, 4 h after the last PLX3603
administration. In short, animals received 10MBq 18F-FDG or
18F-FLT i.v. via the tail vein and animals that received 18F-FDG
were immediately anesthetized with 2% isoﬂurane–O2 and kept
at 37 °C. PET/CT scans were acquired 1 h after 18F-FDG and
18F-FLT injection with an Inveon animal PET/CT scanner (Siemens
Preclinical Solutions, Erlangen, Germany), having an intrinsic
special resolution of 1.5mm (16). The animals were placed in a
supine position on a heated mattress and kept under isoﬂurane
anesthesia throughout the PET/CT scan procedure. PET scans
were acquired for 15min, followed by CT scans for anatomical
reference (spatial resolution, 113μm; 80 kV; 500μA; exposure
time, 300ms). Scans were reconstructed using Inveon
Acquisition Workplace software (version 1.5; Siemens Preclinical
Solutions) using a three-dimensional ordered subset expectation
maximization/maximum a posteriori algorithm with the
following parameters: matrix, 256 × 256× 159; pixel size,
0.43 × 0.43 × 0.8mm; and β-value 1.5, with uniform variance. Af-
ter scan reconstruction, regions of interest (ROI) around the
A375 tumors were manually drawn and the activity in the vol-
ume of interest (VOI) with a threshold set at 50% of the maxi-
mum activity in the ROI was determined (VOI50%). The %ID/g of
the VOI50% was determined by calculating the average of the
E. J. W. GEVEN ET AL.
wileyonlinelibrary.com/journal/cmmi Copyright © 2014 John Wiley & Sons, Ltd. Contrast Media Mol. Imaging 2015, 10 203–210
204
percentage injected dose per gram for the voxels within the
VOI50%, assuming a density of 1 g/ml.
2.6. Immunohistochemistry
Directly following dissection, the A375 tumors were ﬁxed in 4%
paraformaldehyde. Tumors were dehydrated in a graded series
of ethanol, embedded in paraplast and 6μm sections were cut.
Sections were stained for phosphorylated ERK (pERK), glucose
transporter 1 (GLUT1) and Ki67, a marker for cell proliferation.
In short, antigen was retrieved in citrate buffer (10mM, pH 6,
95–100 °C), after which sections were incubated with H2O2 (3%)
to inactivate endogenous peroxidase activity. Sections were
pre-incubated with normal goat serum (20%, pERK and GLUT1)
or normal swine serum (20%, Ki67) to block nonspeciﬁc binding
sites.
Sections were incubated with rabbit-anti-GLUT1 antibody
(1:200, R13-9052-P, Neomarkers, Fremont, CA, USA), rabbit-anti-
pERK antibody (1:100, 4376, Cell Signaling Technology, Danvers,
MA, USA) or rabbit-anti-Ki67 antibody (1:100, RM9106, Thermo
Scientiﬁc, Waltham, MA, USA ) for 2 h. Sections incubated with
the GLUT1 and pERK antibodies were incubated with biotinylated
goat–anti-rabbit secondary antibody (1:200, VectaStain, Vector
Laboratories, Burlingame, CA, USA) for 1 h and followed by incu-
bation for 30min with VectaStain ABC reagent. The sections
incubated with the Ki67 antibody were incubated with swine–
anti-rabbit-peroxidase antibody (1:500, Dako, Glostrup, Denmark).
Peroxidase activity was stained with 3,3′-diaminobenzidine
(Powervision DAB, Immunologic, Duiven, The Netherlands) in the
presence of H2O2 and all sections were counterstained with
hematoxylin.
2.7. Statistical Analysis
All data are presented as mean values ± standard deviation. The
size of the experimental groups (n) is given in parentheses.
Differences between groups were assessed by one-way ANOVA
and Bonferroni post hoc test or by Student’s t-test. Statistical sig-
niﬁcance was set at p< 0.05 (two-tailed) and probabilities are in-
dicated by asterisks (* p< 0.05; ** p< 0.01; *** p< 0.001).
3. RESULTS
3.1. Effect PLX3603 on Tumor Growth
Administration of PLX3603 inhibited A375 tumor growth. Com-
pared with vehicle-treated animals, a dose of 25mg/kg resulted
in a 34% decrease in tumor size after 7 days of treatment
(p= 0.004; Fig. 1). Higher doses (50 and 75mg/kg) resulted in
39 and 29% tumor size reduction after 3 days of treatment
(p= 0.003 and p= 0.02, respectively) and 56 and 49% after 7 days
of treatment (p< 0.0001; Fig. 1).
3.2. 18F-FDG and 18F-FLT Biodistribution Studies
The biodistribution data of 18F-FDG and 18F-FLT in the mice with
s.c. A375 tumors during treatment with PLX3603 are summarized
in Figs 2 and 3, respectively. Increased uptake of 18F-FDG com-
pared with blood levels was observed in all tissues investigated,
while increased 18F-FLT uptake was only observed in spleen, kid-
ney, intestines and bone marrow. A dose-dependent decrease in
18F-FDG uptake in the A375 melanoma xenografts was observed
after treatment with PLX3603. One day after administration of
75mg/kg PLX3603 (three doses) the 18F-FDG uptake in the
tumor (2.9 ± 0.5 %ID/g) was signiﬁcantly reduced by 40%
(p= 0.006) compared with vehicle treatment (4.8 ± 1.0 %ID/g;
Fig. 2a). After 3 days, the administration of both 50mg/kg
(3.4 ± 0.8 %ID/g) and 75mg/kg (3.3 ± 0.6 %ID/g) PLX3603 re-
sulted in signiﬁcantly decreased uptake of 18F-FDG in the tumor
(33 and 35% respectively, p=0.033) compared with vehicle treat-
ment (5.1 ± 0.6 %ID/g; Fig. 2b). Seven days after administration of
the three doses, 25mg/kg (2.9 ± 0.4 %ID/g), 50mg/kg (2.3 ± 0.6 %
ID/g) and 75mg/kg (2.2 ± 0.6 %ID/g), there was a signiﬁcant re-
duction of the uptake of 18F-FDG in the tumor (36, 49 and 51%
respectively, p< 0.0001) compared with vehicle treatment
(4.5 ± 0.6 %ID/g; Fig. 2c).
The administration of PLX3603 had no consistent effect on
18F-FLT uptake in the tumor (Fig. 3): 18F-FLT uptake in the A375
tumor decreased after treatment with 75mg/kg PLX3603 for 1
and 7 days (36%, p=0.041 and 61%, p= 0.039, respectively).
However, this decrease was accompanied by decreased blood
levels of 18F-FLT (35%, p= 0.031 and 32%, p=0.014, respectively;
Fig. 3). It appears that the reduction of uptake of 18F-FLT in the
tumor was the result of enhanced clearance of 18F-FLT from
the blood (Fig. 3). Indeed, 18F-FLT tumor-to-blood ratios did not
signiﬁcantly change compared with tumor-to-blood ratios of ve-
hicle treated animals after 1 (p= 0.933), 3 (p= 0.798) or 7 days
(p= 0.133) of treatment with PLX3603 (data not shown).
3.3. 18F-FDG and 18F-FLT-PET/CT
18F-FDG uptake in A375 melanoma xenografts was clearly visual-
ized in the 3D PET/CT images (Fig. 4a). Three days after the start
of PLX3603 treatment, 18F-FDG uptake in the tumor was lower.
This decrease in 18F-FDG uptake was sustained up to 7 days of
treatment. 18F-FDG uptake was further observed in muscle,
brown adipose tissue, kidney, intestines, heart and brain,
18F-FDG uptake in tail is likely to be injection related. Quantiﬁca-
tion of the 18F-FDG-PET signal in the A375 melanoma xenograft
VOI showed a signiﬁcantly decreased 18F-FDG uptake after 3
(40%, P= 0.012) and 7 days (38%, P=0.006) after the start of
treatment, compared with basal 18F-FDG uptake (Fig. 4b).
18F-FLT PET/CT images revealed a relative low uptake of
18F-FLT in A375 melanoma xenografts, which was not further
reduced after treatment with PLX3603 (Fig. 5a). High uptake of
18F-FLT was observed in the kidney, spleen, intestines and bone
marrow. Quantiﬁcation of the 18F-FLT-PET signal in the A375
Figure 1. Relative s.c. A375 melanoma xenograft size in SCID/beige
mice (n=10) after 1, 3 and 7 days of treatment with PLX3603 (25, 50
and 75mg/kg, administered orally, twice daily) compared with vehicle-
treated animals.
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tumor VOI conﬁrmed that the 18F-FLT uptake in the tumor did
not change during the treatment with PLX3603 (Fig. 5b).
3.4. Immunohistochemistry
Staining for pERK in A375 melanoma xenografts was reduced af-
ter 3 days of treatment with 75mg/kg PLX3603, indicating
inhibition of the MAPK pathway (Fig. 6). The decreased uptake
of 18F-FDG in A375 tumors was not accompanied by reduced ex-
pression of GLUT1 (data not shown), which may be explained by
the relatively small changes in 18F-FDG uptake and the involve-
ment of other proteins, such as hexokinases, in cellular uptake
of 18F-FDG. Similarly, no change in Ki67 expression was observed
in tumors of animals treated with PLX3603, which may be due
Figure 2. 18F-FDG uptake (percentage of injected dose per gram tissue, %ID/g) in tissues of SCID/beige mice (n=5) with s.c. A375 melanoma xeno-
grafts after 1 (a), 3 (b) and 7 days (c) of treatment with PLX3603 (25, 50 and 75mg/kg, administered orally, twice daily.
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to low baseline expression of Ki67 in the A375 tumors (data
not shown).
4. DISCUSSION
The dose- and time-dependent effects of PLX3603 treatment on
18F-FDG-uptake in A375 xenografts observed in this study, show
that 18F-FDG-PET is a potential imaging biomarker to noninva-
sively evaluate the pharmacodynamic effects of the BRAFV600E in-
hibitor PLX3603 on melanoma in an early phase, whereas these
effects could not be assessed with 18F-FLT-PET. Ex vivo
biodistribution analysis revealed a signiﬁcant 40% decrease in
18F-FDG uptake as early as 1 day after administration of
PLX3603 at 75mg/kg, before any change in tumor size was ap-
parent. This decrease persisted during the 7 day dosing regimen
Figure 3. 18F-FLT uptake (%ID/g) in tissues of SCID/beige mice (n=5) with s.c. A375 melanoma xenografts after 1 (a), 3 (b) and 7 days (c) of treatment
with PLX3603 (25, 50 and 75mg/kg, administered orally, twice daily).
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(35 and 51% at 3 and 7 days, respectively). Lower doses of
PLX3603 also resulted in a reduced 18F-FDG uptake in the tumor
after longer exposure: a dose of 50mg/kg resulted in a decreased
18F-FDG uptake after 3 days, whereas at a dose of 25mg/kg
18F-FDG uptake only decreased signiﬁcantly after 7 days. Immu-
nohistochemical analysis of the tumor showed a decreased
expression of pERK after 3 days of treatment with PLX3603,
conﬁrming a pharmacological effect of PLX3603 on the inhibition
of the MAPK pathway.
The observed effects of PLX3603 on 18F-FDG uptake in A375
melanoma xenografts could also be monitored by in vivo
18F-FDG-PET imaging. After 3 and 7 days of treatment with
75mg/kg PLX3603, a 40 and 38% reduction in 18F-FDG uptake
in the A375 xenografts was detected with 18F-FDG-PET, which
is comparable to the ex vivo biodistribution analysis. Other
small-molecule BRAFV600E inhibitors, RAF256 (100mg/kg) and
vemurafenib (50mg/kg), also induced reduced 18F-FDG uptake
in A375 melanoma xenografts (17,18). In patients with metastatic
melanoma, treatment with vemurafenib for 15 days resulted in
an 87% reduction of 18F-FDG uptake, although the reduced up-
take did not predict responses as measured by RECIST (19). The
results of the present study show that 18F-FDG-PET can be used
as pharmacodynamic marker to monitor the dose response and
time course of the response of PLX3603, and therefore 18F-FDG-
PET can be a useful tool in the clinical development of PLX3603,
although caution is needed when extrapolating data from nude
mouse xenograft tumor models to melanoma in men.
A few studies have shed a light on the mechanism how
BRAFV600E inhibition could lead to the reduction of uptake of
18F-FDG in the tumor. Inhibition of the MAPK-pathway, including
inhibition via BRAF, is directly linked to pathways that regulate
glucose metabolism. For instance, inhibition of BRAFV600E results
in the activation of the LKB1-AMP pathway, via ERK, which neg-
atively inﬂuences glucose metabolism (13).
Although in vitro studies have shown reductions in 18F-FLT up-
take in some melanoma cells lines after treatment with the
BRAFV600E inhibitors RAF265 and vemurafenib (17,20), in this
study we show that PLX3603 did not induce decreased 18F-FLT
uptake in the A375 melanoma xenografts, as measured by
ex vivo biodistribution analysis and 18F-FLT-PET. It is not uncom-
mon that 18F-FLT uptake does not reﬂect changes in tumor pro-
liferation. Proliferating tumor cells are not only dependent on
uptake of thymidine via the nucleotide transporter (salvage
pathway), but thymidine can also be synthesized de novo from
deoxyuridine monophosphate via thymidine synthetase. Fur-
thermore, in mice thymidine plasma levels tend to be high and
endogenous thymidine may compete with 18F-FLT (21), which
may explain the low 18F-FLT uptake at baseline and the lack of
reduced 18F-FLT uptake in the A375 xenografts upon BRAFV600E
inhibitor treatment. These results do not exclude 18F-FLT-PET to
Figure 4. (a) 18F-FDG-PET/CT images of a representative mouse at day 1, 1, 3 and 7 of treatment with PLX3603 (75mg/kg, administered orally, twice
daily). White arrows indicate 18F-FDG uptake in the A375 melanoma xenograft. The lower limit of the color scale was set just below the tumor 18F-FDG
signal at day 7. (b) 18F-FDG uptake (%ID/g) in A375 melanoma xenografts as determined from PET signal at 1, 1, 3 and 7 days of treatment with
PLX3603 (75mg/kg, administered orally, twice daily), in three mice.
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monitor the effects of PLX3603 per se, as baseline 18F-FLT in the
present melanoma model was relatively low, possibly precluding
measurement of further reduction of FLT uptake.
This study shows that treatment with the speciﬁc BRAFV600E in-
hibitor PLX3603 results in inhibition of the MAPK-pathway in
A375 melanoma xenografts, as demonstrated by a decreased
pERK expression. The reduced MAPK-pathway activity probably
results in a reduced glucose metabolism in A375 tumors, which
is reﬂected by the decreased uptake of 18F-FDG as assessed by
18F-FDG-PET. Furthermore, 18F-FDG-PET allowed the monitoring
Figure 5. (a) 18F-FLT-PET/CT images of a representative mouse at day -1, 1, 3 and 7 of treatment with PLX3603 (75mg/kg, administered orally, twice
daily). White arrows indicate 18F-FLT uptake in the A375 melanoma xenograft. (b) 18F-FLT uptake (%ID/g) in A375 melanoma xenografts as determined
from PET signal at 1, 1, 3 and 8 days of treatment with PLX3603 (75mg/kg, administered orally, twice daily), in three mice.
Figure 6. pERK immunohistochemistry on sections of A375 melanoma xenografts of SCID/beige mice treated with 75mg/kg PLX3603 (a–c) or vehicle
only (d–f) for 1 (a, d), 3 (b, e) and 7 days (c, f).
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of dose responses and time course effects of PLX3603 activity.
These data demonstrate the potential of 18F-FDG-PET as a phar-
macodynamic marker to noninvasively evaluate the early effects
of the BRAFV600E inhibition by PLX3603 and to further deﬁne op-
timal dosing and timing of PLX3603.
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